These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25758238)

  • 21. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
    Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
    Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
    Miller K; Moul JW; Gleave M; Fizazi K; Nelson JB; Morris T; Nathan FE; McIntosh S; Pemberton K; Higano CS
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
    Caffo O; Lo Re G; Sava T; Buti S; Sacco C; Basso U; Zustovich F; Lodde M; Perin A; Facchini G; Veccia A; Maines F; Barile C; Fratino L; Gernone A; De Vivo R; Pappagallo GL; Galligioni E
    Future Oncol; 2015; 11(6):965-73. PubMed ID: 25760977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
    Bracarda S; Logothetis C; Sternberg CN; Oudard S
    BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Docetaxel-based combination chemotherapy for castration-resistant prostate cancer].
    Urakami S; Shiina H; Igawa M
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():531-7. PubMed ID: 22208039
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
    Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO].
    Rexer H; Graefen M
    Urologe A; 2017 Feb; 56(2):243-244. PubMed ID: 28144693
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
    Harland S; Staffurth J; Molina A; Hao Y; Gagnon DD; Sternberg CN; Cella D; Fizazi K; Logothetis CJ; Kheoh T; Haqq CM; de Bono JS; Scher HI;
    Eur J Cancer; 2013 Nov; 49(17):3648-57. PubMed ID: 23973186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
    Oudard S
    Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
    Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
    Lee DJ; Cha EK; Dubin JM; Beltran H; Chromecki TF; Fajkovic H; Scherr DS; Tagawa ST; Shariat SF
    BJU Int; 2012 Apr; 109(7):968-85. PubMed ID: 22035221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
    Schutz FA; Buzaid AC; Sartor O
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
    Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
    J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; George DJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
    Zhang C; Jing T; Wang F; Gao X; Xu C; Sun Y
    Actas Urol Esp; 2014 Apr; 38(3):184-91. PubMed ID: 24507454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.
    Meulenbeld HJ; Bleuse JP; Vinci EM; Raymond E; Vitali G; Santoro A; Dogliotti L; Berardi R; Cappuzzo F; Tagawa ST; Sternberg CN; Jannuzzo MG; Mariani M; Petroccione A; de Wit R
    BJU Int; 2013 Jan; 111(1):44-52. PubMed ID: 22928785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.